Literature DB >> 11505481

Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.

F S Pasini1, M M Brentani, L P Kowalski, M H Federico.   

Abstract

BACKGROUND: A balance between urokinase-type plasminogen activator (uPA) and its main inhibitor type-1 (PAI-1) appears to be important for cancer invasive behavior. Since uPA/PAI-1 system seems to be regulated by transforming growth factor beta1 (TGFbeta1) in different cell types, our aim was to investigate the relationship between the expression of the three genes and lymph node status in head and neck squamous cell carcinomas (HNSCC) at specific sites.
MATERIALS AND METHODS: uPA, PAI-1, and TGFbeta1 mRNAs were determined by Northern analysis in tumor, and paired normal mucosa samples were obtained from 91 operable HNSCC patients.
RESULTS: In oral cavity, excluding tongue, TGFbeta1, PAI-1, and uPA mRNAs values were consistently lower in the normal tissues than in tumors. In larynx tumors, TGFbeta1 expression was increased, but no statistically significant differences were found for uPA or PAI-1 mRNAs as compared with normal tissues. Tongue tumors overexpressed only uPA mRNA, and uPA levels showed significant parallel variations with TGFbeta1 and PAI-1 mRNAs mainly in pN+ tumors. In oral cavity tumors, an inverse correlation between TGFbeta1 and uPA was observed in pN0 subgroup, elevated uPA mRNA was counterbalanced by high PAI-1 mRNA TGFbeta1, and PAI-1 were not coordinately expressed. Correlations between the three markers were not found in larynx. Hypopharynx tumors, all staged as pN+, expressed the lowest TGFbeta1 mRNA mean values.
CONCLUSIONS: Combined information about TGFbeta1, uPA, and PAI-1 mRNAs may add some clues to the understanding of the pathophysiological role of uPA system in head and neck squamous cell carcinoma. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505481     DOI: 10.1002/hed.1103

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

Review 1.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

2.  Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma.

Authors:  Flavia R R Mangone; M Mitzi Brentani; Suely Nonogaki; Maria Dirlei F S Begnami; Antonio Hugo J F M Campos; Fernando Walder; Marcos B Carvalho; Fernando A Soares; Humberto Torloni; Luiz P Kowalski; Miriam H H Federico
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

3.  Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients.

Authors:  Flavia R R Mangone; Fernando Walder; Simone Maistro; Fátima S Pasini; Carlos N Lehn; Marcos B Carvalho; M Mitzi Brentani; Igor Snitcovsky; Miriam H H Federico
Journal:  Mol Cancer       Date:  2010-05-12       Impact factor: 27.401

4.  Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Authors:  Lusia Sepiashvili; Angela Hui; Vladimir Ignatchenko; Willa Shi; Susie Su; Wei Xu; Shao Hui Huang; Brian O'Sullivan; John Waldron; Jonathan C Irish; Bayardo Perez-Ordonez; Fei-Fei Liu; Thomas Kislinger
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

Review 5.  Matrix metalloproteases in head and neck cancer.

Authors:  Eben L Rosenthal; Lynn M Matrisian
Journal:  Head Neck       Date:  2006-07       Impact factor: 3.147

Review 6.  uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.

Authors:  Miguel Angel Pavón; Irene Arroyo-Solera; Maria Virtudes Céspedes; Isolda Casanova; Xavier León; Ramón Mangues
Journal:  Oncotarget       Date:  2016-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.